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The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular &
Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to
assist physical therapists in their decision-making process when treating patients at risk for
venous thromboembolism (VTE) or diagnosed with a lower extremity deep vein thrombosis
(LE DVT). No matter the practice setting, physical therapists work with patients who are at risk
for or have a history of VTE. This document will guide physical therapist practice in the
prevention of, screening for, and treatment of patients at risk for or diagnosed with LE DVT.
Through a systematic review of published studies and a structured appraisal process, key
action statements were written to guide the physical therapist. The evidence supporting each
action was rated, and the strength of statement was determined. Clinical practice algorithms,
based on the key action statements, were developed that can assist with clinical decision
making. Physical therapists, along with other members of the health care team, should work
to implement these key action statements to decrease the incidence of VTE, improve the
diagnosis and acute management of LE DVT, and reduce the long-term complications of LE
DVT.
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Venous thromboembolism (VTE) isthe formation of a blood clot in adeep vein that can lead to compli-
cations, including deep vein thrombosis
(DVT), a pulmonary embolism (PE), or
postthrombotic syndrome (PTS). Venous
thromboembolism is a serious condition,
with an incidence of 10% to 30% of peo-
ple dying within 1 month of diagnosis,
and half of those diagnosed with a DVT
have long-term complications.1 Even
with a standard course of anticoagulant
therapy, one third of individuals will
experience another VTE within 10
years.1 For those who survive a VTE,
quality of life can be decreased due to
the need for long-term anticoagulation to
prevent another VTE.2
No matter the practice setting, physical
therapists work with patients who are at
risk for or have a history of VTE. Addi-
tionally, physical therapists are routinely
tasked with mobilizing patients immedi-
ately after diagnosis of a VTE. Because of
the seriousness of VTE, the frequency
that physical therapists encounter
patients with a suspected or confirmed
VTE, and the need to prevent future VTE,
the American Physical Therapy Associa-
tion (APTA) in conjunction with the Car-
diovascular & Pulmonary and Acute Care
sections of APTA, support the develop-
ment of this clinical practice guideline
(CPG). It is intended to assist all physical
therapists in their decision making pro-
cess when managing patients at risk for
VTE or diagnosed with a lower extremity
deep vein thrombosis (LE DVT).
In general, CPGs optimize the care of
patients by building upon the best evi-
dence available while examining the
benefits and risks of each care option.3
The VTE Guideline Development Group
(GDG) followed a systematic process to
write this CPG with the overall objective
of providing physical therapists with the
best evidence in preventing VTE, screen-
ing for LE DVT, mobilization of patients
with LE DVT, and management of com-
plications of LE DVT. Specifically, this
CPG will:
• Discuss the role of physical thera-
pists in identifying patients who are
at high risk for a VTE and actions
that can be taken to decrease the
risk of a first or recurring VTE.
• Provide physical therapists with
specific tools to identify patients
whomay have an LE DVT and deter-
mine the likelihood of an LE DVT.
• Assist physical therapists in deter-
mining when mobilization is safe
for a patient diagnosed with an LE
DVT based on the treatment cho-
sen by the interprofessional team.
• Describe interventions that will
decrease diagnosis complications,
such as PTS or another VTE.
• Create a reference publication for
health care providers, patients, fam-
ilies and caretakers, educators, pol-
icy makers, and payers on the best
current practice of physical thera-
pist management of patients at risk
for VTE and diagnosed with an LE
DVT.
• Identify areas of research that are
needed to improve the evidence
base for physical therapist manage-
ment of patients at risk for or diag-
nosed with VTE.
This CPG, which contains 14 key action
statements (Tab. 1), can be applied to
adult patients across all practice settings,
but it does not address or apply to
women who are pregnant or to children.
Additionally, this guideline does not dis-
cuss the management of PE, upper
extremity DVT (UE DVT), or chronic
thromboembolic pulmonary hyperten-
sion (CTEPH). Although primarily writ-
ten for physical therapists, other health
care professionals should find this CPG
helpful in their treatment of patients
who are at risk for or have a diagnosed
VTE.
Background and Need for a
CPG on VTE
Venous thromboembolism is a life-
threatening disorder that ranks as the
third most common cardiovascular ill-
ness, after acute coronary syndrome and
stroke.4 This disorder consists of DVT
and PE, 2 interrelated primary conditions
caused by venous blood clots, along with
several secondary conditions including
PTS and CTEPH.5 From primary and sec-
ondary prevention perspectives, the seri-
ousness of VTE development related to
mortality, morbidity, and diminished life
quality is a worldwide concern.6 The
incidence of VTE differs greatly among
countries. For example, the United States
ranges from 70 to 120 cases per 100,000
inhabitants per year, and in Europe there
are between 140 and 240 cases per
100,000 inhabitants per year, with sud-
den death being a frequent outcome.7
Deep vein thrombosis is a serious, yet
potentially preventable, medical condi-
tion that occurs when a blood clot forms
in a deep vein, most commonly in the
calf, thigh, or pelvis. A life-threatening,
acute complication of LE DVT is PE. This
complication occurs when the clot dis-
lodges, travels through the venous sys-
tem, and causes a blockage in the pulmo-
nary circulatory system. A proximal LE
DVT, defined as occurring in the popli-
teal vein or veins more cephalad, is asso-
ciated with an estimated 50% risk of PE if
not treated, as compared with approxi-
mately 20% to 25% of LE DVTs below the
knee.8 Approximately 1 in 5 individuals
with acute PE die almost immediately,
and 40% will die within 3 months.9 In
those who survive PE, significant cardio-
pulmonary morbidity can occur, most
notably CTEPH.
Chronic thromboembolic pulmonary
hypertension can be the result of a single
PE, multiple PEs, or recurrent PEs.
Acutely, PE causes an obstruction of
flow. This narrowing of the lumen may
lead to reduced oxygenation and pulmo-
nary hypertension. Chronically, the
infarction of lung tissue following PE
may result in a reduction of vasculariza-
tion and concomitant pulmonary hyper-
tension. Over time, the workload
imposed on the right heart increases and
contributes to right heart dysfunction
and then failure.10 A new syndrome,
post-PE syndrome, has more recently
been proposed to capture those patients
with persistent abnormal cardiac and
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Table 1.
Key Action Statementsa
Number Statement Key Phrase
1 Physical therapists should advocate for a culture of mobility and physical activity unless
medical contraindications for mobility exist.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Advocate for a culture of mobility and physical
activity
2 Physical therapists should screen for risk of VTE during the initial patient interview and
physical examination.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Screen for risk of VTE
3 Physical therapists should provide preventive measures for patients who are identified
as high risk for LE DVT. These measures should include education regarding signs
and symptoms of LE DVT, activity, hydration, mechanical compression, and referral
for medication.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Provide preventive measures for LE DVT
4 Physical therapists should recommend mechanical compression (eg, IPC, GCS) when
individuals are at high risk for LE DVT.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Recommend mechanical compression as a
preventive measure for LE DVT
5 Physical therapists should establish the likelihood of an LE DVT when the patient has
pain, tenderness, swelling, warmth, or discoloration in the lower extremity.
(Evidence Quality: II; Recommendation Strength: B–Moderate)
Identify the likelihood of LE DVT when signs
and symptoms are present
6 Physical therapists should recommend further medical testing after the completion of
the Wells criteria for LE DVT prior to mobilization.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Communicate the likelihood of LE DVT and
recommend further medical testing
7 When a patient has a recently diagnosed LE DVT, physical therapists should verify
whether the patient is taking an anticoagulant medication, what type of
anticoagulant medication, and when the anticoagulant medication was initiated.
(Evidence Quality: V; Recommendation Strength: D–Theoretical/Foundational)
Verify the patient is taking an anticoagulant
8 When a patient has a recently diagnosed LE DVT, physical therapists should initiate
mobilization when therapeutic threshold levels of anticoagulants have been reached.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Mobilize patients who are at a therapeutic
level of anticoagulation
9 Physical therapists should recommend mechanical compression (eg, IPC, GCS) when a
patient has an LE DVT.
(Evidence Quality: II; Recommendation Strength: B–Moderate)
Recommend mechanical compression for
patients with LE DVT
10 Physical therapists should recommend that patients be mobilized, once
hemodynamically stable, following IVC filter placement.
(Evidence Quality: V; Recommendation Strength: P–Best Practice)
Mobilize patients after IVC filter placement
once hemodynamically stable
11 When a patient with a documented LE DVT below the knee is not treated with
anticoagulation and does not have an IVC filter and is prescribed out of bed
mobility by the physician, the physical therapist should consult with the medical
team regarding mobilizing versus keeping the patient on bed rest.
(Evidence Quality: V; Recommendation Strength: P–Best Practice)
Consult with the medical team when a patient
is not anticoagulated and without an IVC
filter
12 Physical therapists should screen for fall risk whenever a patient is taking an
anticoagulant medication.
(Evidence Quality: III; Recommendation Strength: C–Weak)
Screen for fall risk
13 Physical therapists should recommend mechanical compression (eg, intermittent
pneumatic compression, graduated compression stockings) when a patient has signs
and symptoms suggestive of PTS.
(Evidence Quality: I; Recommendation Strength: A–Strong)
Recommend mechanical compression when
signs and symptoms of PTS are present
14 Physical therapists should monitor patients who may develop long-term consequences
of LE DVT (eg, PTS severity) and provide management strategies that prevent them
from occurring to improve the human experience and increase quality of
life. (Evidence Quality: V; Recommendation Strength: P–Best Practice)
Implement management strategies to prevent
future VTE
a VTEvenous thromboembolism, LE DVTlower extremity deep vein thrombosis, IPCintermittent pneumatic compression, GCSgraduated compression
stockings, IVCinferior vena cava, PTSpostthrombotic syndrome.
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pulmonary function who do not meet
the criteria for CTEPH.5 These condi-
tions are associated with diminished
function and lowered quality of life.11
Beyond the threat of PE and its sequelae,
LE DVT may lead to long-term complica-
tions. Postthrombotic syndrome is the
most frequent complication and devel-
ops in up to 50% of these patients even
when an appropriate anticoagulant is
used.12,13 A clot remaining in the vein of
the lower extremity can obstruct blood
flow, leading to venous hypertension.
Additionally, damage to the vein itself
occurs and leads to inflammation and
necrosis of the vein, which eventually
are removed by phagocytic cells, leading
to venous hypertension. This impaired
blood flow can lead to classic symptoms
of PTS, which often includes chronic
aching pain, intractable edema, limb
heaviness, and leg ulcers.10 This chronic
pathology can cause serious long-term ill
health, impaired functional mobility,
poor quality of life, and increased costs
for the patient and the health care system.
Across various practice settings, physical
therapists encounter patients who are at
risk for VTE, may have an undiagnosed
LE DVT, or have recently been diagnosed
with an LE DVT. The physical therapist’s
responsibility to every patient is 5-fold:
(1) prevention of VTE, (2) screening for
LE DVT, (3) contributing to the health
care team in making prudent decisions
regarding safe mobility for these
patients, (4) patient education and
shared decision making, and (5) preven-
tion of long-term consequences of LE
DVT. Such decisions should always be
made in collaboration with the referring
physician and other members of the
health care team (ie, it is assumed that
such decisions will not be made in isola-
tion and that the physical therapist will
communicate with the medical team).
Due to the long-standing controversy
regarding mobilization versus bed rest
following VTE diagnosis and with the
development of new anticoagulation
medications, the physical therapy com-
munity needs evidence-based guidelines
to assist in clinical decision making. This
CPG is intended to be used as a reference
document to guide physical therapist
practice in the prevention of, screening
for, and treatment of patients at risk for
or diagnosed with LE DVT. This CPG is
based on a systematic review of pub-
lished studies on the risks of early ambu-
lation in patients with diagnosed DVT
and on other established clinical guide-
lines on prevention, risk factors, and
screening for VTE and PTS. In addition to
providing practice recommendations,
this guideline also addresses gaps in the
evidence and areas that warrant further
investigation.
Methods
The GDG, which comprised physical
therapists with special interest in acute
care and cardiovascular and pulmonary
practice, was appointed by the Cardio-
vascular & Pulmonary and the Acute
Care sections of APTA to develop a
guideline to address the physical thera-
pist’s role in the management of VTE.
Specifically, the role of mobility was
identified as a major issue facing both
sections. Models used by the APTA Pedi-
atric Section for its CPG on physical ther-
apy management of congenital muscular
torticollis14 were primarily used to
develop this CPG, as well as other APTA-
supported CPGs and international pro-
cesses. In July 2012, the GDG initiated
the process under the guidance of APTA
and developed a list of topic areas to be
covered by the CPG. In addition, topic
areas were solicited from clinicians with
content experience in the area of VTE
who volunteered to assist. A resultant list
of topic areas was developed to deter-
mine the scope of the CPG and provided
the GPG with limits to the literature
search.
Literature Review
A search strategy was developed and per-
formed by a librarian to identify literature
published between May 1, 2003, and
May 2014 addressing mobilization
and anticoagulation therapy to prevent
and treat VTE. Searches were performed
in the following databases: PubMed,
CINAHL, Web of Science, Cochrane
Database of Systematic Reviews, Data-
base of Abstracts of Reviews of Effects
(DARE), and the Physiotherapy Evidence
Database (PEDro). Controlled vocabular-
ies, such as MeSH and CINAHL headings,
were used whenever possible in addition
to key words. Results were limited to
articles written in English. The search
strategy by key words, MeSH terms, and
databases is shown in Table 2. Using this
search strategy, 350 out of 8,652
abstracts and citations of relevance were
obtained from Web of Science, CINAHL,
PubMed, and Cochrane Database of Sys-
tematic Reviews.
Clinical practice guidelines published
between 2003 and 2014 were searched
including the same key words and MeSH
terms using the National Guideline Clear-
inghouse (NGC, http://www.guideline.
gov/) database and the Trip database
(http://www.tripdatabase.com/). The
NGC database identified 169 guidelines,
of which 40 were deemed as appropriate
to be reviewed. Three additional guide-
lines were identified through the Trip
database, and the appropriate target pop-
ulations were included.
Method: Literature Review
Procedures
The results of the literature and guideline
searches were distributed to the mem-
bers of the GDG. One member of the
group reviewed a list of citations, and
another member performed a second
review of the same list of citations. Arti-
cles were included based on whether
key topics were addressed and the
appropriate target populations were
included. Case reports and pediatric arti-
cles were excluded. The GDG, along
with clinicians and academicians who
volunteered from both the Cardiovascu-
lar & Pulmonary Section and the Acute
Care Section, were invited to review the
identified literature.
Reliability of appraisers was established
prior to articles being reviewed. Selected
articles were reviewed by 3 individuals
who used 1 of 3 critical appraisal tools
adapted from an evidence-based practice
textbook to evaluate each according to
its type (ie, critical appraisal for studies
of prognosis, diagnosis, or interven-
tion).15 The Assessment of Multiple Sys-
tematic Reviews (AMSTAR) tool was
used for systematic reviews.16 Selected
diagnosis, prognosis, and intervention
articles and systematic reviews were crit-
ically appraised by the GDG to establish
test standards. Interrater reliability
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among the 4 core group members was
first established on test articles. Volun-
teers completed critical appraisals of the
test articles to establish interrater reliabil-
ity. Volunteers qualified to be appraisers
with agreement of 90% or more. Apprais-
ers were randomly paired to read each of
the remaining diagnostic, prognostic, or
intervention articles. Discrepancies in
scoring between the readers were
resolved by a member of the GDG.
Clinical practice guidelines were
reviewed that fit the scope of this CPG
and the patient population. Guidelines
were included based on whether key
topics were addressed and the target
populations were included. The results
of the CPG search were reviewed by one
member of the GDG. Four additional
clinical expert volunteers underwent
training in the Appraisal of Guidelines for
Research and Evaluation II (AGREE II)17
tool to evaluate CPGs with subsequent
reliability testing being performed on all
reviewers.
Levels of Evidence and Grades of
Recommendations
The GDG followed a previously pub-
lished process on developing physical
therapy CPGs.14 Table 3 lists criteria used
to determine the level of evidence asso-
ciated with each practice statement,
Table 2.
Search Strategy by Key Words, MeSH Terms, and Databases
Key Words MeSH Terms Databases
DVT
“Venous Thrombosis”
“Deep Vein Thrombosis”
VTE
“Venous Thromboembolism“
“Pulmonary Embolism”
Walking
Walk
Ambulation
Ambulate
Ambulated
Movement
Mobility
Immobilization
Immobilisation
“Mobility Limitation”
“Motor Activity”
“Early Ambulation”
“Early Activization”
“Early Activisation”
“Early Mobilization”
“Early Mobilisation”
Anticoagulants
Anticoagulant
Anticoagulation
Dabigatran
Desirudin
Ximelagatran
Edoxaban
Rivaroxaban
Apixaban
Betrixaban
“YM150”
Razaxaban
“Factor Xa Inhibitor”
“Direct Thrombin Inhibitors”
“Direct Thrombin Inhibitor”
Coumadin
Warfarin
Fondaparinux
Idraparinux
“International Normalized Ratio“
“INR”
“Prothrombin Time”
“Vena Cava Filter*”
“Intermittent Pneumatic Compression Devices”
“Compression Stockings”
“Compression Socks”
“Compression Hose”
“Compression Hosiery”
“Venous Thrombosis”
“Pulmonary Embolism”
“Walking”
“Movement”
“Immobilization”
“Mobility Limitation”
“Motor Activity”
“Early Ambulation”
“Activities of Daily Living”
“Anticoagulants”
“Coumarins”
“Fibrin Modulating Agents”
“Factor Xa/antagonists and inhibitors”
“Thrombosis/prevention and control”
“Antithrombins”
“Citric Acid”
“Heparinoids”
“Vitamin K/antagonists and inhibitors”
“Antithrombin Proteins”
“Fibrinolytic Agents”
“International Normalized Ratio”
“Prothrombin Time”
“Vena Cava Filters”
“Intermittent Pneumatic Compression Devices”
“Stockings, Compression”
PubMed
CINAHL
Web of Science
Cochrane Database of Systematic Reviews
Database of Abstracts of Reviews of Effects (DARE)
Physiotherapy Evidence Database (PEDro)
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with level I as the highest level of evi-
dence and level V as the lowest level of
evidence. Table 4 presents the criteria
for the grades assigned to each action
statement. The grade reflects the overall
and highest levels of evidence available
to support the action statement.
Statements that received an A or B grade
should be considered as well supported.
The CPG lists each key action statement
followed by rating of level of evidence
and grade of the recommendation.
Under each statement is a summary pro-
viding the supporting evidence and clin-
ical interpretation. The statements are
organized in Table 1 according to the
action statement number, the statement,
and the key phrase or action statement.
AGREE II Review
This CPG was evaluated by 5 GPG mem-
bers using the AGREE II instrument to
assess the methodological quality of the
guideline. The 5 members scored this
guideline as high quality according to the
AGREE II tool (eAppendix 2, available at
ptjournal.apta.org).
External Review Process by
Stakeholders
This CPG underwent 2 formal reviews.
First, draft reviewers were invited stake-
holders representing the American Col-
lege of Chest Physicians, Society for Vas-
cular Nursing, physical therapy clinicians
and researchers, and patient representa-
tives. The second draft was posted for
public comment on both the APTA Car-
diovascular & Pulmonary Section and
Acute Care Section websites; notices
were sent via email and an electronic
newsletter to Cardiovascular & Pulmo-
nary Section members, literature apprais-
ers, and clinicians who inquired about
the CPG during its development.
Document Structure
The action statements organized in Table
1 are introduced with their assigned rec-
ommendation grade, followed by a stan-
dardized content outline generated by
BRIDGE-Wiz software (http://gem.med.
yale.edu/BRIDGE-Wiz/).18 Each state-
ment has a content title, a recommenda-
tion in the form of an observable action
statement, indicators of the evidence
quality, and the strength of the recom-
mendation. The action statement profile
describes the benefits, harms, and costs
associated with the recommendation; a
delineation of the assumptions or judg-
ments made by the GDG in formatting
the recommendation; reasons for any
intentional vagueness in the recommen-
dation; and a summary and clinical inter-
pretation of the evidence supporting the
recommendation. The Delphi process
was used to determine level of evidence
and recommended strength for each key
action statement. Each member of the
GPG reviewed the supporting evidence
for each key action statement and voted
Table 3.
Levels of Evidencea
Level Criteria
I Evidence obtained from high-quality diagnostic studies, prognostic or prospective studies,
cohort studies or randomized controlled trials, meta-analyses or systematic reviews
(critical appraisal score 50% of criteria)
II Evidence obtained from lesser-quality diagnostic studies, prognostic or prospective studies,
cohort studies or randomized controlled trials, meta-analyses or systematic reviews (eg,
weaker diagnostic criteria and reference standards, improper randomization, no
blinding, 80% follow-up) (critical appraisal score 50% of criteria)
III Case-controlled studies or retrospective studies
IV Case studies and case series
V Expert opinion
a Reprinted from Kaplan S, Coulter C, Fetters L. Developing evidence-based physical therapy
clinical practice guidelines. Pediatr Phys Ther. 2013;25:257–270, with permission of Wolters Kluwer
Health Inc.
Table 4.
Grades of Recommendation for Action Statementsa
Grade Recommendation Quality of Evidence
A Strong A preponderance of level I studies but at least 1 level I
study directly on the topic support the
recommendation.
B Moderate A preponderance of level II studies but at least 1 level
II study directly on the topic support the
recommendation.
C Weak A single level II study at 25% critical appraisal score
or a preponderance of level III and IV studies,
including statements of consensus by content
experts support the recommendation.
D Theoretical/foundational A preponderance of evidence from animal or cadaver
studies, from conceptual/theoretical
models/principles, or from basic science/bench
research, or published expert opinion in peer-
reviewed journals supports the recommendation.
P Best practice Recommended practice based on current clinical
practice norms, exceptional situations where
validating studies have not or cannot be performed
and there is a clear benefit, harm, or cost, and/or
the clinical experience of the guideline
development group.
R Research There is an absence of research on the topic, or
higher-quality studies conducted on the topic
disagree with respect to their conclusions. The
recommendation is based on these conflicting
conclusions or absent studies.
a Reprinted from Kaplan S, Coulter C, Fetters L. Developing evidence-based physical therapy clinical
practice guidelines. Pediatr Phys Ther. 2013;25:257–270, with permission of Wolters Kluwer Health Inc.
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on level of evidence and strength of rec-
ommendation independent of the other
group members using a Google survey
upon which all votes were tallied and
then reported.
Scope of the Guideline
This CPG uses literature available from
2003 through 2014 to address the follow-
ing aspects of physical therapists’ man-
agement of patients with potential or
diagnosed VTE. The CPG addresses these
aspects of VTE management via 14
action statements. Clinical practice algo-
rithms (Figs. 1, 2, and 3), based on the
key action statements, were developed
that can assist with clinical decision
making.
Key Action Statements
With Evidence
Action Statement 1: Advocate for
a culture of mobility and physical
activity
Physical therapists and other health
care practitioners should advocate
for a culture of mobility and physical
activity. (Evidence Quality: I; Recom-
mendation Strength: A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefits: Decreased likelihood of LE
DVT and/or PE and/or PTS
Risk, Harm, Cost: Injuries from falls
Benefit-Harm Assessment: Preponder-
ance of benefit
Value Judgments: Physical therapists
should advocate for mobility in all situa-
tions due to the evidence on the benefits
of activity and risks associated with inac-
tivity and bed rest except when there
could be a risk of harm (eg, emboli
depositing in the pulmonary system).
Intentional Vagueness: None
Role of Patient Preferences: As the
evidence for risks associated with inac-
tivity is strong and with little associated
risk of mobility in the absence of throm-
boembolism, patients should be edu-
Figure 1.
Algorithm for screening for risk of venous thromboembolism (VTE).
Figure 2.
Algorithm for determining likelihood of a lower extremity deep vein thrombosis (LE DVT). DVTdeep vein thrombosis.
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cated regarding the benefits of mobility
and encouraged to maintain mobility as
much as possible to decrease the risk of
adverse outcomes.
Exclusions: None
Summary of evidence
Reduced mobility is a known risk factor
for VTE, yet the quantity and duration of
the reduced mobility that defines degree
of risk for VTE are not known.19–21 Sig-
nificant variability exists in the literature
regarding reduced mobility and the
resulting risk for VTE.22 Patients who
were ambulatory were found to be at
increased risk for developing a VTE with
a standing time of 6 or more hours (odds
ratio [OR]1.9) or resting in bed or a
chair (OR5.6).23 Likewise, a significant
correlation exists between loss of mobil-
ity status for 3 or more days and the
presence of LE DVT on duplex
ultrasound.24
When additional risk factors for VTE are
present in an individual who has any
reduction in mobility, the risk for VTE is
significantly increased. Increased age
serves as an example. One study of hos-
pitalized patients older than 65 years
found reduced mobility to be an inde-
pendent risk factor for VTE. The risk
increased based on the degree of immo-
bility, and relative risk scores were
derived according to the degree of immo-
bility (Tab. 5).19,25 The OR risk was
found to be higher in older patients with
more severe limitation of mobility (bed
rest versus wheelchair) and when the
loss of mobility was more recent (15
days versus 30 days).
Recent national guidelines have associ-
ated reduced mobility with increased
risk for VTE.20,26 The National Institute
for Health and Care Excellence (NICE)
guidelines present strong recommenda-
tions for the need to regard patients
undergoing surgery and patients with
trauma as at an increased risk of VTE.
When patients undergo surgery with an
anesthesia time of greater than 90 min-
utes or if the surgical procedure involves
the pelvis or lower limb and anesthesia
time is greater than 60 minutes, the risk
is much greater. Individuals who are
admitted acutely for surgical reasons or
admitted with inflammatory or intra-
abdominal conditions also are at high
risk for developing a VTE. These same
guidelines emphasized the need to iden-
tify all individuals who are expected to
have any significant reductions in mobil-
ity to be at risk for VTE and to mobilize
them as soon as possible.20 The Ameri-
can College of Chest Physicians (ACCP)
guidelines emphasize prevention of VTE
in patients not undergoing surgery by
incorporating nonpharmacological pro-
phylaxis measures, including frequent
ambulation, calf muscle exercise, and sit-
ting in the aisle and mobilizing the lower
extremities when traveling (Grade 2C
recommendations).26,27
Previously, when individuals were diag-
nosed with an LE DVT, they were placed
on bed rest due to the concern that
Figure 3.
Algorithm for mobilizing patients with known lower extremity deep vein thrombosis. DVTdeep vein thrombosis, LMWHlow-molecular-
weight heparin, UFHunfractionated heparin, NOACnovel oral anticoagulants, INRinternational normalized ratio, IVCinferior vena
cava. *If started on Coumadin, LMWH usually also started. Use LMWH guidelines for mobilization decision in these situations.
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ambulation would cause clot dislodg-
ment and lead to a potentially fatal PE.
However, a meta-analysis compiled data
from 5 randomized controlled trials
(RCTs) on more than 3,000 patients and
concluded that early ambulation follow-
ing diagnosis of an LE DVT was not asso-
ciated with a higher incidence of a new
PE or progression of LE DVT compared
with bed rest.28 Rather, there was a
lower incidence of new PE and overall
mortality in those patients who engaged
in early ambulation. Similar findings, as
well as more rapid resolution of pain,
were reported in a systematic review
that included 7 RCTs and 2 prospective
observational studies.29 The importance
of mobility is further discussed in key
Action Statement 8.
In summary, mobility should be encour-
aged in patients while in the hospital and
when discharged to prevent the compli-
cations associated with immobility. In
addition, mobility is recommended for
those diagnosed with VTE once thera-
peutic anticoagulant levels have been
reached (see Action Statement 8).
Action Statement 2: Screen for
risk of VTE
Physical therapists should screen for
risk of VTE during the initial patient
interview and physical examination
(Evidence Quality: I; Recommenda-
tion Strength: A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefits: Prevention or early detection
of LE DVT
Risk, Harm, and Cost: Adverse effects
of prophylaxis interventions
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: Physical thera-
pists should work within their health
care system to determine specific algo-
rithms or risk assessment models (RAMs)
to use.
Role of Patient Preferences: None
Exclusions: None
Summary of evidence
The Guide to Physical Therapist Prac-
tice states that the physical therapist
examination is a comprehensive screen-
ing and specific testing process leading
to diagnostic classification or, as appro-
priate, to a referral to another practitio-
ner.30 Understanding the factors that
place individuals at risk for a VTE is
important for all physical therapists. Dur-
ing the patient interview, physical ther-
apists should ask questions and review
the medical history to determine
whether the patient is at risk for LE DVT.
Risk factors include previous venous
thrombosis or embolism, age, active can-
cer or cancer treatment, severe infec-
tion, oral contraceptives, hormonal
replacement therapy, pregnancy or
given birth within the previous 6 weeks,
immobility (bed rest, flight travel, frac-
tures), surgery, anesthesia, critical care
admission, central venous catheters,
inherited thrombophilia, and obesity.
The relationship between particular risk
factors and presence of LE DVT has been
found through retrospective and pro-
spective studies and identified as having
support from level I evidence in other
CPGs.19,31–34
The need for all health care providers to
screen for risk of LE DVT through
system-wide approaches has been high-
lighted by the US Agency for Healthcare
Research and Quality,35 the Finnish Med-
ical Society,31 and the Scottish Intercol-
legiate Guidelines Network,36 and such
screening is strongly recommended by
each of these groups. Furthermore, the
importance of screening was strongly
supported in a 2008 multinational cross-
sectional study of patients from more
than 350 hospitals across 32 countries.
The findings revealed that 39.5% of
patients at risk for VTE were not receiv-
ing appropriate prophylaxis.37 Hospital-
wide strategies were recommended to
assess patients’ VTE risk and to monitor
whether those at risk received appropri-
ate prophylaxis.
To facilitate and standardize the process
of screening for risk within health care
systems and across professions, RAMs
should be considered.36,38 Risk assess-
ment models use a checklist to deter-
mine whether risk factors for LE DVT are
present and each risk factor is assigned a
point value. If a set point level is reached,
the patient is considered at an increased
risk, and more aggressive prophylactic
interventions can be used. There are
numerous examples of RAMs in the liter-
ature, including the Padua score for
assessing VTE risk in hospitalized
patients,39 the IMPROVE VTE RAM,40 the
Autar DVT Risk Assessment Scale,41 and
the Geneva Risk Score.42 None have
been shown to be superior to others
through direct comparisons, and, for this
reason, the GDG cannot recommend a
single RAM. It is more important that
physical therapists work within their
health care system to understand and
even help develop an overall VTE proto-
col that uses an agreed-upon tool for VTE
risk assessment.
In summary, given the risks and harms
associated with a VTE and the relation-
Table 5.
Reduced Mobility as a Risk Factor for Venous Thromboembolism19,25,a
Degree of
Immobility OR 95% CI P
Normal 1.0
Limited 1.73 1.08, 2.75 .02
Wheelchair 30 d 2.43 1.37, 4.30 .002
Bed rest 30 d 2.73 1.20, 6.20 .02
Wheelchair 15–30 d 3.33 1.26, 8.84 .02
Bed rest 15–20 d 3.37 1.00, 11.29 .05
Wheelchair 15 d 4.32 1.50, 12.45 .007
Bed rest 15 d 5.64 2.04, 15.56 .0008
a ORodds ratio, CIconfidence interval.
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ship of VTE incidence to the presence of
risk factors, physical therapists should
screen for VTE risk. These results should
be communicated with the rest of the
health care team.
Action Statement 3: Provide
preventive measures for LE DVT
Physical therapists should provide
preventive measures for LE DVT
for patients who are identified as
being at risk for LE DVT. These mea-
sures should include education
regarding signs and symptoms of LE
DVT, activity, hydration, mechanical
compression, and referral for medi-
cation assessment. (Evidence Qual-
ity: I; Recommendation Strength:
A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefits: Prevention of LE DVT
Risk, Harm, Cost: None to minimal
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: None
Role of Patient Preferences: Patients
may or may not choose to adhere to
preventive measures. There is a role for
having shared decision making with
regard to their priorities.
Exclusions: None
Summary of evidence
For individuals who are at risk for LE
DVT, preventive measures should be ini-
tiated immediately, including education
regarding leg exercises, ambulation,
proper hydration, mechanical compres-
sion, and assessment regarding the need
for medication referral.
Education is a key factor in risk reduction
of VTE and should be provided for
patients who are at elevated risk for LE
DVT and for their families. Documenta-
tion of the patient’s understanding of
these concepts also should be
included.43 Topics that should be
included in this education program for
these patients and their families are: risk
factors for DVT, possible consequences
of DVT, interventions to decrease the
risk of DVT, signs and symptoms of DVT
and importance of seeking medical help
if DVT is suspected, importance of
follow-up monitoring, importance of
treatment adherence, and medication
issues (eg, regimen, adverse side effects
and interactions, dietary restrictions).44
Immobilization is one of the primary risk
factors for VTE and is a problem for
patients in the home and in acute care
settings and long-term care facilities.
Immobility, as it relates to residents in
long-term care facilities, is defined by the
presence of at least one of the following:
lower limb cast, bedridden, bedridden
except for bathroom privileges, recent
decreased ability to walk at least 3.1 m
(10 ft) for a least 72 hours, and inability
to walk at least 3.1 m (10 ft).45 Patients
who are limited to a chair or bed greater
than half the day during waking hours
are considered at elevated risk for VTE.
The acuteness and severity of the immo-
bility determines the elevated risk level
of developing VTE.19
As immobility also occurs with long-
distance travel, travelers on planes for
greater than 2 to 3 hours are also at
increased risk for LE DVT. The ACCP27
recommends that such travelers ambu-
late frequently, perform calf muscle exer-
cises, sit in an aisle seat, and use below-
the-knee compression stockings with at
least 15 to 30 mm Hg compression (2C
recommendation).
Action Statement 4: Recommend
mechanical compression as a
preventive measure for DVT
Physical therapists should recom-
mend mechanical compression (eg,
intermittent pneumatic compres-
sion [IPC], graded compression
stockings [GCS]) when individuals
are at moderate to high risk
for LE DVT or when anticoagulation
is contraindicated. (Evidence Quali-
ty: I; Recommendation Strength:
A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefits: Prevents LE DVT without
increasing the risk of bleeding
Risk, Harm, Cost: Improper fit can lead
to skin irritation, ulceration, or interrup-
tion of blood flow.
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: Specific types
of mechanical compression were not
recommended. Physical therapists
should work within their health care sys-
tem to develop institution-specific
protocols.
Role of Patient Preferences: Ease of
use, comfort level, and ability to operate
mechanical compression equipment
properly should be evaluated with each
patient.
Exclusions: Patients who have severe
peripheral neuropathy, decompensated
heart failure, arterial insufficiency, der-
matologic diseases, or lesions may have
contraindications to selective mechani-
cal compression modes.
Summary of evidence
The influence of mechanical compres-
sion on LE DVT or PE prophylaxis was
examined in 7 systematic reviews.46–52
The populations included patients who
were in postoperative recovery from a
variety of surgical procedures, with or
without pharmacological prophylaxis.
Also included were airline travelers of
varying VTE risk levels. These studies
supported that GCS used alone signifi-
cantly decreased the incidence of LE
DVT or PE and that this mechanical com-
pression method provided additional
benefit when combined with other pro-
phylactic methods. Although GCS was
the method of mechanical compression
in all 7 of these publications, the descrip-
tive features of the GCS were
inconsistent.
Screening to identify VTE risk is essential
and will identify which, if any, mechan-
ical compression method is appropriate
to implement. In the CPG of the Japanese
Circulation Society for PE and LE DVT
prevention, elastic stockings or IPC, IPC
or anticoagulation, and anticoagulation
plus IPC or elastic stockings are recom-
mended for postoperative patients with
elevated risk.53 The Institute for Clinical
Systems Improvement guidelines for VTE
prophylaxis recommend that if contrain-
dications exist for both low-molecular-
weight heparin (LMWH) and low-dose
unfractionated heparin (UFH) and there
is high risk for VTE but not high risk for
bleeding, fondaparinux or low-dose aspi-
rin or IPC be used.43 One example would
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be someone with a history of heparin-
induced thrombocytopenia (HIT). Inter-
mittent pneumatic compression or GCS
are recommended for patients who are
acutely or critically ill and who are bleed-
ing or are at high risk for major bleeding,
until bleeding risk decreases, at which
time pharmacological thromboprophy-
lactic methods can be substituted.38,54
A systematic review of 6 RCTs looked at
patients at high risk for VTE who under-
went various surgical procedures to
assess the effectiveness of IPC combined
with pharmacological prophylaxis ver-
sus single modality usage.55 Combining
IPC with an anticoagulant (eg, LMWH)
was more effective in VTE prevention
than either IPC or anticoagulant use
alone, which is consistent with the CPG
recommendation offered by the Japanese
Circulation Society.
In summary, there is substantial support-
ive evidence for the use of mechanical
compression methods for patients with
medical conditions or undergoing sur-
gery,36,56–60 prolonged air-flight travel-
ers,6,47,49 and patients in long-term care
facilities.45 For those people at increased
risk for VTE, the use of GCS or IPC, with
or without anticoagulation therapy, is
considered to be beneficial. The evi-
dence is inconsistent, however, in
describing the optimal protocols for use
of GCS, elastic stockings, or IPC. Poten-
tial for rare circulatory compromise with
the use of GCS (ie, knee or thigh length)
warrants proper fitting and careful mon-
itoring of skin condition by the patient
and physical therapist.
Action Statement 5: Identify the
likelihood of LE DVT when signs
and symptoms are present
Physical therapists should establish
the likelihood of LE DVT when the
patient has pain, tenderness, swell-
ing, warmth, or discoloration in the
lower extremity. (Evidence Quality:
II; Recommendation Strength: B–
Moderate)
Action statement profile
Aggregate Evidence Quality: Level II
Benefit: Early intervention and preven-
tion of adverse effects of LE DVT
Risk, Harm, Cost: None
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: Although the Wells
criteria for LE DVT are recommended by
this GDG, there are other tools that may
be preferred by other interprofessional
teams.
Intentional Vagueness: None
Role of Patient Preferences: None
Exclusions: None
Summary of evidence
The major signs and symptoms of LE
DVT include pitting edema, pain, tender-
ness, swelling, warmth, redness or dis-
coloration (erythema), and prominent
superficial veins.36,45,61,62 The presence
of these signs and symptoms should raise
the suspicion of an LE DVT, but they
cannot be used alone in the diagnostic
process.31,61 The likelihood of LE DVT
should be established through use of a
standardized tool. This recommendation
is supported by numerous CPGs26,36,61,63
and a meta-analysis.62 A standardized tool
uses the presence of clinical features of
an LE DVT to determine the likelihood
that an LE DVT is present and guides the
selection of the most appropriate test to
diagnose an LE DVT. Physical therapists
should use a standardized tool as part of
their examination process when signs
and symptoms of LE DVT are present.
The results of the assessment should
then be communicated with the medical
team.
The Wells criteria for LE DVT are the
most commonly used tool to determine
likelihood of LE DVT (Tab. 6).21,64 Orig-
inally, the Wells criteria for LE DVT used
a 3-tier risk stratification of low, moder-
ate, and high. A score of 3 or greater was
high risk, a score of 1 to 2 was moderate
risk, and a score of 0 or below was low
risk. In a study of 593 patients, 16% had
an LE DVT. When the rate of LE DVT was
examined in each stratification level, the
rates were 3% (95% confidence interval
[CI]1.7%, 5.9%), 16.6% (95% CI12%,
23%), and 74.6% (95% CI63%, 84%) for
low, moderate, and high risk, respec-
tively. Other studies have shown a clear
distinction in the rate of LE DVT among
the 3 risk stratification levels.62,65 A 2014
systematic review showed that, as the
score on the Wells criteria increased, so
did the likelihood of an LE DVT.66 This
relationship has held up across multiple
subgroups of patients, including outpa-
tients, inpatients, those with malignancy,
and patients grouped by sex and previ-
ous history of an LE DVT.
In 2003, the Wells criteria for LE DVT
were modified to a 2-stage stratification
(ie, LE DVT likely or LE DVT unlikely),
and a history of previous LE DVT was
added to the tool.67 Reducing the model
to 2 levels made it easier to use and did
not compromise patient safety when
used in conjunction with a D-dimer test.
Individuals with 2 or more points were
categorized as likely, and those with less
than 2 points were categorized as
unlikely. In a study of 1,082 outpatients,
27.9% (95% CI23.9%, 31.8%) of those
classified as likely had a proximal LE DVT
or a PE. Of those patients classified as
unlikely, 5.5% (95% CI3.8%, 7.6%) had
a proximal LE DVT or a PE.
Beyond the Wells criteria for LE DVT,
other risk stratification tools have been
developed, but there are limited compar-
ison studies among the tools. One exam-
ple is the Oudega rule, developed for
primary care providers. When compared
to the Wells criteria for LE DVT, it has
similar effectiveness.68,69
The Wells criteria for LE DVT have a long
and well-supported history of success-
fully stratifying risk or likelihood of LE
DVT across patient populations and prac-
tice settings; therefore, the GDG recom-
mends this tool for risk stratification.
Physical therapists should advocate for
its use with their interdisciplinary team
and determine the best way to commu-
nicate the results and risks.
Action Statement 6:
Communicate the likelihood of
LE DVT and recommend further
medical testing
Physical therapists should recom-
mend further medical testing after
the completion of the Wells criteria
for LE DVT prior to mobilization
(Evidence quality: I; Recommenda-
tion strength: A–Strong)
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Action statement profile
Aggregate Evidence Quality: Level I
Benefit: Risk stratification can ensure
proper diagnostic testing is completed
Risk, Harm, Cost: None
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: None
Role of Patient Preferences: None
Exclusions: None
Summary of evidence
Once the Wells criteria for LE DVT are
complete, medical testing can be
ordered by the medical team to diagnose
or rule out an LE DVT. The selection of
which medical test is beyond the scope
of physical therapist practice, but there
is benefit in understanding why tests are
selected and how results guide the diag-
nostic process. If a patient is classified as
unlikely to have an LE DVT, the over-
whelming recommendation is for the
medical team to order a D-dimer test
over other more costly and invasive
tools.26,31,43,44,70 Within the referenced
CPGs, the evidence is rated as level I,
with grade of A to B for the recommen-
dation. The D-dimer test is a measure of
the breakdown or degradation of cross-
linked fibrin, which increases in the
presence of a thrombosis. In patients
with an LE DVT–unlikely classification
and a negative D-dimer test, fewer than
1% have an LE DVT, and studies report
sensitivity in the upper 90% to 100%.71–73
These patients need no further testing
and can be considered safe to
mobilize.26,31,36,43,70
Although the D-dimer test has high sen-
sitivity, it has poor specificity. A positive
D-dimer test does not indicate a definite
LE DVT. A range of conditions, such as
older age, infections, burns, and heart
failure, can lead to an elevated D-dimer
test, and hospitalized individuals have a
high rate of false positives when the
D-dimer is used for a suspected LE
DVT.74 When a patient who is LE DVT–
unlikely has a positive or high D-dimer
level, further testing is necessary. Most
guidelines recommend a duplex ultra-
sound to confirm an LE DVT.26,43,44,63
There is some debate on the type of
ultrasound that is ordered, but this factor
is beyond the focus of these guidelines. If
the ultrasound confirms an LE DVT, med-
ical treatment should be initiated and
mobilization postponed. If the ultra-
sound is negative, the patient is safe to
mobilize.
A patient rated as LE DVT–likely should
immediately undergo a duplex ultra-
sound.26,31,44,63 Individuals in the DVT–
likely category will test positive on the
D-dimer test, so the D-dimer test has lit-
tle value. If the ultrasound is negative,
the physical therapist should consider
the patient safe to mobilize. If the ultra-
sound is positive, the physical therapist
should defer mobility until medical treat-
ment has achieved therapeutic levels.
In summary, the results of the Wells cri-
teria for LE DVT should guide the selec-
tion of medical testing. Following the
results of the medical testing, the physi-
cal therapist can then make a decision
about when it is safe to mobilize the
patient.
Action Statement 7: Verify the
patient is taking an
anticoagulant
When a patient has a recently
diagnosed LE DVT, the physical ther-
apist should verify whether the
patient is taking an anticoagulant
medication, what type of anticoagu-
lant medication, and when the
anticoagulant medication was
initiated. (Evidence Quality: V;
Recommendation Strength: D–
Theoretical/Foundational)
Action statement profile
Aggregate Evidence Quality: Level V
Benefit: Decreased risk of a PE in
patients who are adequately anticoagu-
lated
Risk, Harm, Cost: Risk of bleeding with
anticoagulation, risk of adverse effects
with restrictions in inactivity, and cost of
new anticoagulants may be prohibitive
in those with inadequate pharmacy
insurance coverage.
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: Intentional vague-
ness. This CPG has provided therapeutic
ranges for anticoagulants that have been
provided by the manufacturers due to
the limited evidence beyond this.
Although the recommendation strength
is weak based on scientific evidence, the
GDG considers it prudent to follow the
manufacturer’s recommendations.
Role of Patient Preference: Patients
should be informed of the importance
for continuing anticoagulation upon dis-
charge from the hospital as different anti-
Table 6.
Two-Level Deep Vein Thrombosis (DVT) Wells Criteria Scorea
Clinical Feature Points
Active cancer (treatment ongoing, within 6 mo, or palliative) 1
Paralysis, paresis, or recent plaster immobilization of the lower extremities 1
Recently bedridden for 3 d or longer or major surgery within 12 wk
requiring general or regional anesthesia
1
Localized tenderness along the distribution of the deep venous system 1
Entire leg swollen 1
Calf swelling at least 3 cm larger than asymptomatic side 1
Pitting edema confined to the symptomatic leg 1
Collateral superficial veins (nonvaricose) 1
Previously documented DVT 1
Alternative diagnosis at least as likely as DVT 2
Clinical probability simplified score
DVT likely 2 points or more
DVT unlikely Less than 2 points
a Reprinted from Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of
suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227–1235. © 2003 Massachusetts Medical
Society. Reprinted with permission from the Massachusetts Medical Society.
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coagulants require monitoring, cost, and
modification of diet and bleeding risk.
Exclusions: None
Summary of evidence
Anticoagulants are the primary defense
used to prevent and treat an LE DVT and
consequent PE or PTS. Contrary to pop-
ular belief, anticoagulants do not actively
dissolve a blood clot but instead prevent
new clots from forming. Although anti-
coagulants are often referred to as blood
thinners, they do not actually thin the
blood. This class of drugs works by alter-
ing certain chemicals in the blood nec-
essary for clotting to occur. Conse-
quently, blood clots are less likely to
form in the veins or arteries, and yet
continue to form where needed.
Although anticoagulants do not break
down clots that have already formed,
they do allow the body’s natural clot lysis
mechanisms to work normally to break
down clots that have formed.
Once an LE DVT is diagnosed, anticoag-
ulant therapy is initiated, most com-
monly with LMWH. Anticoagulant ther-
apy will help to stop an existing clot
from getting larger and prevent any new
clots from forming. In addition, LMWH
has been shown to stabilize an existing
clot and resolve symptoms through the
drug’s anti-inflammatory properties,
making a clot less likely to migrate as an
embolus.
A patient diagnosed with an LE DVT is at
risk of developing a PE; therefore, mobil-
ity is contraindicated until intervention is
initiated to reduce the chance of emboli
traveling to the lungs.75–79 According to
the ACCP guidelines on antithrombotic
therapy, anticoagulation is the main
intervention and should be initiated as
soon as possible (level I, strong evi-
dence).26,43,44,61 If the patient is at a high
risk for bleeding, the primary contraindi-
cation to anticoagulation, then medica-
tions may not be prescribed. Therefore,
prior to initiating mobility out of bed, a
physical therapist should review all med-
ications the patient has been prescribed
and verify that the patient is taking an
anticoagulant. The physical therapist
should next consult with the medical
team regarding appropriateness of mobil-
ity. Although physical therapists do not
play a role in recommending the antico-
agulant of choice, they should identify
which anticoagulant the patient has been
prescribed and date and time of the first
dose. This approach will assist the phys-
ical therapist in determining when the
patient has reached a therapeutic dose,
and consequently, when mobility may be
initiated safely.
The current options for anticoagulation
include UFH, LMWH, Coumadin (Bristol-
Myers Squibb, New York, New York)
(warfarin), fondaparinux, and oral
thrombin or Xa inhibitors (eTable, avail-
able at ptjournal.apta.org). Most patients
with a confirmed diagnosis of LE DVT or
PE are prescribed a form of LMWH or
fondaparinux (both given with subcuta-
neous injections).31,44,61 Low-molecular-
weight heparin is principally used to
treat any LE DVT below the knee, at
thigh level, and more proximal
thrombi.31 It is the anticoagulant of
choice for pregnancy and for active can-
cer and the primary choice of physicians
for treatment of VTE in the outpatient or
home setting due to ease of use and low
incidence of side effects.31,43,61 Low-
molecular-weight heparin is used in most
cases except when a patient has renal
dysfunction or a creatinine clearance less
than 30 mL/min. Concomitant Coumadin
use may be started and provided for 3
days, with subsequent international nor-
malized ratio (INR) values being deter-
mined. Most individuals will continue
with their initial anticoagulant (LMWH or
fondaparinux) for 3 to 6 months for the
first episode of diagnosed thrombosis. If
Coumadin is given concomitantly, they
will likely be removed from the initial
anticoagulant and continued on Couma-
din for 3 to 6 months.44,80
Anti-Xa levels can be used to monitor
LMWH. However, evidence does not
support the use of anti-Xa assay levels for
predicting thrombosis and bleeding
risk.81 Pharmacokinetic studies on
LMWH report that maximum anti-factor
Xa and antithrombin IIa activities occur 3
to 5 hours after subcutaneous injection
of LMWH.82 The optimal therapeutic
anti-Xa levels for treatment are 0.5 to 1.0
U/mL. Due to the fact that LMWH is
excreted primarily by the kidneys,
increased bleeding complications have
been reported when LMWH is used in
patients with renal insufficiency and
other populations. Therefore, precau-
tions for bruising and bleeding with
physical therapy interventions should be
taken when LMWH is used in patients
with kidney injury or dysfunction,
patients in extreme weight ranges,
patients who are pregnant, and neonates
and infants.63
Unfractionated heparin is indicated for
individuals with high bleeding risk
(eTable) or renal disease. Patients with
established or severe renal impairment
are defined as those with an estimated
glomerular filtration rate of less than 30
mL/min/1.73 m2. Unfractionated heparin
is often prescribed and dosed to achieve
therapeutic levels quickly. Lower speeds
of infusion are usually given in acute cor-
onary syndromes, whereas higher speeds
of infusion are given with VTE. Several
institutions have transitioned from mon-
itoring heparin with anti-factor Xa levels
instead of activated partial thromboplas-
tin time (aPTT) due to influencing factors
that can alter aPTT levels.83 One study
has shown anti-Xa detects therapeutic
levels faster than aPTT (patients with
UFH achieved therapeutic anticoagula-
tion in approximately 24 hours com-
pared with patients monitored with
aPTT, which averaged 48 hours).83
Patients with a documented PE, includ-
ing those who are hemodynamically
unstable, are often prescribed UFH, and
similar aPTT monitoring should be
reviewed by the physical therapist see-
ing the patient.44
Coumadin is usually not the first medica-
tion choice for anticoagulation due to
the length of time to achieve peak ther-
apeutic levels. Coumadin is typically
introduced on day 1 during administra-
tion of another anticoagulation, usually
with LMWH or UFH.61 The loading anti-
coagulant (LMWH or UFH) is continued
for at least 5 days until an INR greater
than 2.0 is achieved for at least 24 hours,
prior to discontinuing the loading antico-
agulant, and first episodes of VTE should
be treated with a target INR range of
2.5.80 The UFH or LMWH is often discon-
tinued when the INR is greater than
2.0.61
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Fondaparinux (Arixtra, GlaxoSmith-
Kline, Research Triangle Park, North Car-
olina) is similar to LMWH, is monitored
using anti-Xa assays, and is often used
when individuals need treatment or pro-
phylaxis for VTE but have a history of
HIT.43 The maximal therapeutic dosage
is reached in approximately 2 to 3
hours.43,79 Fondaparinux also is used for
thromboprophylaxis in patients with
medical and surgical conditions, as is
LMWH.63
Both UFH and LMWH are associated with
HIT, defined as an immune-mediated
reaction to heparins. Heparin-induced
thrombocytopenia can occur in 2% to 3%
of patients treated with UFH and in
approximately 1% of patients treated
with LMWH.43 Heparin-induced throm-
bocytopenia will result in a paradoxical
increased risk for venous and arterial
thrombosis, and this risk lasts approxi-
mately for 100 days following initial reac-
tion. Therefore, patients with a history of
HIT should not receive either LMWH or
UFH with subsequent VTE.43,84 Treat-
ment for anticoagulation in individuals
with HIT involves using fondaparinux or
other thrombin-specific inhibitors such
as lepirudin or argatroban. Indicators of
HIT are: skin lesion reaction at injection
site, systemic reaction to a bolus admin-
istration of heparin, and 50% decrease in
platelet count from normal ranges while
on heparin. Indicators of delayed-onset
HIT are: thromboembolic complications
1 to 2 weeks after receiving the last dose
of LMWH or UFH, and mild-to-moderate
thrombocytopenia.
Mobility decisions with an individual
receiving Coumadin are based on the ini-
tial anticoagulant and not Coumadin.
Concern regarding exercise and out-of-
bed activity should be raised for elevated
INRs greater than 4.0 when patients are
taking warfarin.85 If the INR is between
4.0 and 5.0, resistive exercises should be
avoided, with participation in light exer-
cise only (eg, rating of perceived exer-
tion 11) due to increased risk of bleed-
ing.85 Ambulation should be restricted if
gait is unsteady to prevent falls.85 The
likelihood of bleeding rises steeply as
INR increases above 5.0.86–88 If the INR
is greater than 5.0, discussion should be
held with the referring physician regard-
ing patient safety. When the INR is
greater than 6.0, the medical team
should consider bed rest until the INR is
corrected.85,86 In most cases, INRs can
be corrected within 2 days.85 When
reversal of anticoagulation is needed for
surgery and the patient is taking Couma-
din, fresh frozen plasma is the choice to
replace the anticoagulation.86
New oral anticoagulant drugs (direct
thrombin inhibitors and direct factor Xa
inhibitors) are growing in popularity due
to their ease of use (no laboratory mon-
itoring, no adverse dietary or other drug
interactions) and their rapid time to peak
therapeutic levels. In addition, there
appears to be less risk of cerebral hem-
orrhage, as occurs in vitamin K antago-
nists.86 Rivaroxaban (Xarelto, Janssen
Pharmaceuticals Inc, Titusville, New Jer-
sey), dabigatran (Pradaxa, Boehringer
Ingelheim Pharmaceuticals Inc, Ridge-
field, Connecticut), and apixaban
(Eliquis, Bristol-Myers Squibb Co) are the
3 new oral anticoagulant drugs in use at
this time (refer to eTable for dosage,
method of delivery, and peak
therapeutic-level time frames). The new
oral anticoagulant drugs are recom-
mended by the American Academy of
Orthopaedic Surgeons for hip and knee
arthroplasty but have not been tested or
recommended for individuals who have
cancer, are undergoing treatment for
cancer, or are pregnant.89 There are con-
cerns regarding reversal of anticoagula-
tion with these medications. However,
reconstructed recombinant factor Xa or
activated charcoal have both been pro-
posed as antidotes.89,90 The time for
reversal is the amount of time to elimi-
nate the drug from the body, which is
based on the drug’s half-life, usually
within 12 to 24 hours. With all anticoag-
ulants there is a risk of bleeding. There-
fore, in addition to the risk of VTE, phys-
ical therapists should be aware of and
assess for risk of bleeding in all patients.
Factors associated with high risk of
bleeding are: active bleeding; acute
stroke; acquired bleeding disorders (eg,
acute liver failure); concurrent use of
anticoagulants known to increase the
risk of bleeding (eg, Coumadin with an
international normalized ratio 2); lum-
bar puncture, epidural, or spinal anesthe-
sia expected to be given within next 12
hours; thrombocytopenia (platelet count
less than 7,500); uncontrolled systolic
hypertension (defined as blood pressure
of 230/120 mm Hg or higher), and
untreated inherited bleeding disorders,
such as hemophilia or von Willebrand
disease.20
Action Statement 8: Mobilize
patients who are at a therapeutic
level of anticoagulation
When a patient has a recently diag-
nosed LE DVT, physical therapists
should initiate mobilization when
therapeutic threshold levels of anti-
coagulants have been reached. (Evi-
dence Quality: I; Recommendation
Strength: A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefit: Decreased risk of subsequent
LE DVT or PE; decreased risk of adverse
effects of bed rest
Risk, Harm, Cost: Risks associated with
use of anticoagulants include increased
risk of bleeding. If an anticoagulant is not
at a therapeutic level, there may be an
increased risk of PE with mobilization.
Benefit-Harm Assessment: Preponder-
ance of benefit
Value Judgments: The evidence for
mobility to prevent VTE is strong,
although the evidence on when to initi-
ate mobility may not be as strong and is
based on the patient achieving the ther-
apeutic level of the anticoagulant. Phys-
ical therapists should mobilize patients
as soon as possible after diagnosis of VTE
as long as the risk of PE is decreased.
Achieving the therapeutic level of the
anticoagulant has been shown to dimin-
ish the risk of developing a PE.
Intentional Vagueness: Specific antico-
agulants or their therapeutic levels are
not recommended. Instead, evidence-
based guidelines and algorithms have
been provided for guidance. Physical
therapists should work within their
health care system to develop institution-
specific protocols.
Role of Patient Preference: Patients
should be aware of the anticoagulation
they are prescribed and the effect that
the anticoagulant will have on their life-
style (eg, amount of medical monitoring,
risk of bleeding, foods to avoid, risk of
brain bleed). In addition, patients should
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be informed regarding the risk of immo-
bility in developing further VTE and the
benefit of mobility.
Exclusions: The risk of bleeding is pres-
ent when anyone takes anticoagulants.
However, patients with HIT, a history of
HIT, recent bleeding events, or increased
risk of bleeding should be prescribed
treatment other than anticoagulation,
including mechanical compression or
intravenous filters.
Summary of evidence
Patients who have a documented LE DVT
and have reached therapeutic levels of
the prescribed anticoagulant should be
mobilized out of bed and ambulate to
prevent venous stasis. In doing so,
deconditioning is minimized, length of
hospital stay may be shortened, and
other adverse effects of prolonged bed
rest (eg, decubiti) can be avoided. A
common concern for mobilizing a
patient with an LE DVT is that the clot
will dislodge and embolize to the lungs,
causing a potentially fatal PE. However,
early ambulation has been shown to lead
to no greater risk of PE than bed rest for
people with a diagnosed LE DVT who
have been treated with anticoagulants.28
A meta-analysis showed the absence of a
higher risk of new PE or other adverse
clinical events when individuals were
ambulated instead of kept on bed rest.28
The studies included in this meta-analysis
had differences in the timing of ambula-
tion following initiation of anticoagula-
tion. Nevertheless, the conclusion
arrived at was that “early” ambulation
was possible as soon as the level of effec-
tive anticoagulation had been reached.28
In 2 earlier systematic reviews, 1 with 3
studies totaling 300 patients91 and 1 with
9 studies,23 similar conclusions were
reported. A potentially reduced risk for
extension of a proximal LE DVT and
reduced long-term symptoms of PTS
with early mobility was reported, dem-
onstrating the benefits of early mobiliza-
tion of patients having LE DVT.29
In 2012, the ACCP published guidelines
on antithrombotic therapy and preven-
tion of thrombosis provided a moderate
strength recommendation that patients
with an acute LE DVT should receive
early ambulation over initial bed rest
because of the potential to decrease PTS
and improve quality of life.27
In summary, early mobilization of
patients with an LE DVT who are antico-
agulated does not put the patient at
increased risk of PE. Early mobilization
has added benefits. The GDG recom-
mends mobilizing patients with an LE
DVT once anticoagulation is initiated and
therapeutic levels have been achieved.
Based on the evidence that exists on time
to peak therapeutic levels of the antico-
agulants (refer to eTable), expert consen-
sus exists to recommend early ambula-
tion of individuals with an LE DVT who
are receiving anticoagulation and have
reached their peak therapeutic levels
based on the specific anticoagulation
medication they are prescribed.
Action Statement 9: Recommend
mechanical compression for
patients with LE DVT
Physical therapists should recom-
mend mechanical compression (eg,
IPC, GCS) when a patient has an LE
DVT. (Evidence Quality: II; Recom-
mendation Strength: B–Moderate)
Action statement profile
Aggregate Evidence Quality: Level II
Benefit: Secondary prevention of recur-
rent DVT/PE or PTS and faster resolution
of LE DVT signs and symptoms
Risk, Harm, Cost: Improper fit can lead
to skin irritation, ulceration, or interrup-
tion of blood flow
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: Types of
mechanical compression were not rec-
ommended. Physical therapists should
work within their health care system to
develop institution-specific protocols.
Role of Patient Preference: Ease of
use, comfort level, and ability to operate
mechanical compression equipment
properly should be discussed with
patients and their families or caregivers.
Exclusions: Patients who have severe
peripheral neuropathy, arterial insuffi-
ciency, dermatologic diseases, or lesions
may have contraindications to selective
mechanical compression modes.
Summary of evidence
In the ninth edition (2012) CPG by the
ACCP, recommendations pertaining to
mechanical compression based on
moderate-quality data for patients with
diagnosed LE DVT were given.91 For
patients with acute symptomatic LE DVT
and in those having PTS, GCS were sug-
gested based on studies using at least 30
mm Hg of pressure at the ankle. In
patients with severe PTS of the leg not
adequately relieved with GCS, a trial with
IPC was suggested.
Systematic reviews pertaining to the
adjuvant use of mechanical compression
garments for patients who are anticoag-
ulated and have acute VTE (eg, LE DVT)
while on bed rest or with early ambula-
tion compared with controls provide
supportive evidence for their use.92 The
7 RCTs in these reviews concluded that
mechanical compression lowered the
relative risk for progression of a throm-
bus or the development of a new
thrombus.
Two earlier RCTs conducted over 2 years
on patients who had symptomatic, first-
occurrence proximal LE DVTs con-
cluded that knee-length elastic GCS with
interface pressures of 30 to 40 mm Hg at
the ankle reduced the incidence of mild,
moderate, and severe PTS compared
with controls who did not wear GCS.93,94
In stark contrast, a more recent random-
ized placebo-controlled multicenter trial
with 410 patients having a first proximal
LE DVT followed for 2 years (ie, SOX
trial) did not support the routine wearing
of GCS (ie, knee length at 30–40 mm Hg
compared with 5 mm Hg placebo
knee-length stockings) after LE DVT.95
Two additional RCTs96,97 on patients
who were anticoagulated and had acute
LE DVT combined early ambulation with
the wearing of either inelastic (rigid)
stockings above the knee (ie, zinc plaster
Unna boots providing 50 mm Hg of inter-
face pressure at the ankle) or thigh-
length elastic stockings (ie, providing an
interface pressure of 30 mm Hg at the
ankle) compared with control patients
on bed rest. The combination of GCS
with ambulation resulted in a faster
resolution of pain and swelling and an
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increased quality-of-life outcome
measure.
In summary, the evidence to support
mechanical compression methods as
effective treatment interventions for sec-
ondary VTE prevention varies according
to patient VTE risk profile, acute (eg,
hemodynamic stability) versus chronic
(eg, PTS concern) status, degree of signs
(eg, swelling) and symptoms (eg, pain),
and consideration for potentially harmful
outcomes (eg, skin lesions). Whether
used adjunctively along with anticoagu-
lants, alone as in patients when antico-
agulant use is contraindicated, or in com-
bination (eg, ambulation plus GCS) with
or without anticoagulation, mechanical
compression use has mostly been favor-
able. Controversy persists, however,
regarding whether to support the rou-
tine use of mechanical compression (eg,
GCS) for LE DVT management and sec-
ondary prevention. Studies tend to sug-
gest that having GCS compression forces
at the ankle, regardless of whether elastic
or rigid, is beneficial when 30 mm Hg,
especially when combined with early
ambulation. Regardless of whether the
mode of mechanical compression is by
GCS or another means (eg, IPC), the opti-
mal mechanical compression treatment
strategy has yet to be identified.98
Action Statement 10: Mobilize
patients after inferior vena cava
(IVC) filter placement once
hemodynamically stable
Physical therapists should mobilize
patients after IVC filter placement
once they are hemodynamically sta-
ble and there is no bleeding at the
puncture site. (Evidence Quality: V;
Recommendation Strength: P–Best
Practice)
Action statement profile
Aggregate Evidence Quality: Level V
Benefits: Decreased risk of PE reduced
in-hospital fatality rate in patients who
are stable and those who are unstable
Risk, Harm, Cost: IVC complications
and potential overuse of IVC filters may
increase costs
Benefit-Harm Assessment: Preponder-
ance of benefit over harm for patients
who have an acute proximal LE DVT and
contraindications to anticoagulants
Value Judgments: An IVC filter is valu-
able for patients at high risk who are
unable to be given anticoagulants.
Intentional Vagueness: None
Role of Patient Preference: None
Exclusions: Patients with contraindica-
tions to IVC filter placement
Summary of evidence
Inferior vena cava filter placement is a
type of percutaneous endovascular inter-
vention for venous thromboembolic dis-
ease and is usually performed by an inter-
ventional radiologist. Venous access is
via the right internal jugular or right fem-
oral veins. The best placement location
for the IVC filter to prevent lower
extremity and pelvic VTE is just inferior
to the renal veins.99 Table 7 lists the
indications and contraindications for IVC
filter placement. In general, IVC filters
are used to prevent PE in patients who
are thought to be at high risk for LE DVT
or PE, have contraindications to antico-
agulants, or for whom medications have
not been effective. Findings are mixed
regarding the effectiveness of IVC filters
in preventing PE, and there are risks asso-
ciated with IVC filter placement (Tab. 8).
Following placement of an IVC filter, the
patient should be mobilized once he or
she is hemodynamically stable and there
is no bleeding at the puncture site.99
Physical therapists should monitor ambu-
lation and mobility to ensure patient
safety and to determine the appropriate
level of required assistance prior to the
patient being discharged.99
Action Statement 11: Consult
with the medical team when a
patient is not anticoagulated and
without an IVC filter
When a patient with a documented
LE DVT below the knee is not treated
with anticoagulation and does not
have an IVC filter and is prescribed
out of bed mobility by the physician,
the physical therapist should consult
with the medical team regarding
mobilizing versus keeping the
patient on bed rest. (Evidence Qual-
ity: V; Recommendation Strength:
P–Best Practice)
Action statement profile
Aggregate Evidence Quality: Level V
Benefits: Mobility has demonstrated a
decreased risk of VTE
Risk, Harm, Cost: Potential increased
risk of PE should the LE DVT embolize
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: As movement spe-
cialists, physical therapists recommend
mobilization over bed rest due to the
documented benefits of earlymobilization.
Intentional Vagueness: Specific guide-
lines are not provided because it is rare
that a patient will not have anticoagu-
lants prescribed or an IVC filter in this
country. Each patient should be consid-
ered individually.
Role of Patient Preferences: Patients
should be informed of the risks and ben-
efits of bed rest and inactivity and of
mobilization.
Exclusions: Any LE DVT present above
the knee
Table 7.
Indications and Contraindications to Inferior Vena Cava Filter Placement138
Absolute Indications Relative Indications
Contraindication to anticoagulation Large free-floating proximal deep vein thrombosis
Therapeutic anticoagulation is unable to be
achieved or maintained
Therapeutic anticoagulation not achieved
Venous thromboembolism with decreased
cardiopulmonary reserve
Poor adherence to anticoagulation medication
High risk of complication from anticoagulation
Absolute Contraindications Relative Contraindications
Complete, chronic thrombosis of the
inferior vena cava filter
Severe, uncorrectable coagulopathy
Inability to gain central venous access Bacteremia or sepsis
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Summary of evidence
There may be times when a patient has a
diagnosed LE DVT but no medical inter-
ventions are initiated. The patients may
have contraindications for receiving anti-
coagulant medications or they do not
meet the criteria for an IVC (eg, in palli-
ative care or hospice care). In these sit-
uations, a consult with the primary phy-
sician or medical team should guide the
decision to mobilize the patient. Con-
tinuing to remain on bed rest will only
increase the risk of additional VTE and
other adverse effects of immobilization.
At some point, the patient needs to
return to daily activities, and it might be
appropriate to begin mobilization even
though an untreated LE DVT is present.
In other situations, the reason for not
addressing the LE DVT may be short
term. It may be wise to wait until antico-
agulation can begin. The physical thera-
pist needs to discuss all of these factors
with the interprofessional team and the
patient when making a clinical judgment
about mobilization. Although a physician
may order physical therapy to increase
the physical activity level of a patient, it
is the physical therapist’s clinical deci-
sion whether to mobilize the patient
based on the available information about
the patient’s LE DVT and risk status.
Action Statement 12: Screen for
fall risk
Physical therapists should screen for
fall risk whenever a patient is taking
an anticoagulant medication. (Evi-
dence Quality: III; Recommendation
Strength: C–Weak)
Action statement profile
Aggregate Evidence Quality: Level III
Benefits: Decreased risk of hemorrhage
due to falls
Risk, Harm, Cost: Immobility versus
risk of falling
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: Fall prevention is a
prudent step in managing patients who
are at increased risk for bleeding.
Role of Patient Preference: None
Exclusions: None
Summary of evidence
A major bleed event is a possible compli-
cation in patients taking an anticoagulant
medication. Use of oral anticoagulants
increases the risk of intracerebral bleeds
by 7 to 10 times.100 Individuals who fall
while on long-term anticoagulation have
higher rates of mortality than those not
on these medications due to a subse-
quent major bleed.101,102 However, the
benefits of being on an anticoagulant out-
weigh the risk of a major bleed.103,104
Therefore, patients at high risk for falls
are not automatically excluded from
receiving anticoagulants and will receive
these medications when it is considered
medically beneficial.
Age is considered a major risk factor for
falls. People 75 years of age and older
have the highest rate of falls, and 1 in 3
individuals over the age of 65 years fall
each year.105,106 Because of the risk of
falls associated with age, the National
Institute for Health and Care Excellence,
the American Geriatrics Society, and the
US Preventive Services Task Force all rec-
ommend screening for fall risk in all
older adults.107–109 Individuals should be
asked about feelings of unsteadiness and
falls over the last year. If a fall or
unsteadiness has been reported, further
assessment of strength, balance, and
other risk factors should be completed.
In general, the population of individuals
on anticoagulants is made up of older
adults who would benefit from fall risk
screening.4,110 The Centers for Disease
Control and Prevention’s Stopping
Elderly Accidents, Deaths and Injuries
(STEADI) toolkit provides physical ther-
apists and interprofessional team mem-
bers with an evidence-based tool to
improve fall prevention in clinical
practice.
Action Statement 13:
Recommend mechanical
compression when signs and
symptoms of PTS are present
Physical therapists should recom-
mend mechanical compression (eg,
IPC, GCS) when a patient has signs
and symptoms suggestive of PTS.
(Evidence Quality: I; Recommenda-
tion Strength: A–Strong)
Action statement profile
Aggregate Evidence Quality: Level I
Benefit: Faster resolution of LE DVT
signs and symptoms and decreasing PTS
severity
Risk, Harm, Cost: Improper fit can lead
to skin irritation, ulceration, and inter-
ruption of blood flow.
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: The specific
types of mechanical compression were
not recommended. Physical therapists
should work within their health care sys-
tem to develop institution-specific
protocols.
Role of Patient Preference: Ease of
use, comfort level, and ability to operate
mechanical compression equipment
properly should be discussed with the
patient and caregiver.
Exclusions: Patients who have severe
peripheral neuropathy, arterial insuffi-
ciency, dermatologic diseases, or lesions
may have contraindications to selective
mechanical compression modes.
Table 8.
Complications Related to Inferior Vena Cava Filters138,139
Insertion Complications Thrombotic Complications
Hematoma at insertion site Insertion site thrombosis
Misplacement Inferior vena cava filter thrombosis
Pneumothorax New or progression of deep vein thrombosis
Inferior vena cava damage/wall penetration New or progression of pulmonary embolism
Filter migration Postthrombotic syndrome
Air embolism
Carotid artery puncture
Arteriovenous fistula
Infection
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Summary of evidence
Approximately 1 in 3 patients with LE
DVT will experience PTS within 5 years,
and in 5% to 10% of these patients, PTS
occurs in its most severe form as venous
ulceration.13,111,112 The potential exists
that should infection develop, septice-
mia or septic shock could result.113
Patients with PTS experience chronic
complaints of leg pain secondary to the
DVT, which may include the sense of the
leg feeling heavy, cramping, and itching,
and, in severe cases, venous ulcer-
ation.13,98,114 The pathogenesis of PTS is
thought to be related to venous hyper-
tension. As the thrombus initiates an
inflammatory response, venous valves
may become damaged during this pro-
cess of thrombus resolution, which is
often incomplete over time. The dam-
aged venous valves cause valvular reflux,
and as remodeling of the vein wall
occurs, they may become stiff and con-
tribute to increased outflow resistance,
which increases blood pressure in the
veins. This increase in transluminal pres-
sure causes leakage into the interstitial
space, leading to edema and skin
changes. Microcirculation and blood
supply to the leg muscles become com-
promised, which can lead to venous
ulcerations in the more severe instances
of PTS.98 With clinical findings of PTS
being similar to that of an acute LE DVT,
concern is raised regarding the negative
impact that PTS may have on a person’s
quality-of-life experience.13,111,113,115–117
For reasons described above, physical
therapists should consider screening all
patients with a history of LE DVT, past
and current, for signs and symptoms of
PTS. Once PTS is suspected, a specific
and sensitive rating instrument referred
to as the Villalta scale can be used to
grade the severity of PTS.117–120
A meta-analysis conducted on 5 RCTs
determined that venous compression
stockings or compression bandages are
effective in reducing PTS in patients.119
In patients with LE DVT receiving GCS
compared with controls, mild-to-
moderate PTS occurred in 64 (22%) of
296 patients treated with venous com-
pression compared with 106 (37%) of
284 controls. Severe PTS occurred in 14
(5%) of 296 patients treated compared
with 33 (12%) of 284 controls. Develop-
ment of any degree of PTS occurred in 89
(26%) of 338 patients treated compared
with 150 (46%) of 324 controls. Thus,
GCS reduces the severity of PTS,
although there was a wide variation in
the type of stockings used, time interval
from diagnosis to application of stock-
ings, and duration of treatment.
Two Cochrane reviews, separated by 1
year, were conducted to determine the
treatment interventions of IPC or GCS
according to PTS severity. Findings from
the first review based on 2 RCTs112
included favorable trends using higher
pressures of IPC over that of lower pres-
sures and that there was not enough evi-
dence to support the use of elastic GCS
(30–40 mm Hg pressures at the ankle
versus placebo stockings) in patients
with mild-to-moderate PTS severity. The
second review, based on 3 RCTs,120 pro-
vided statistically significant evidence
that elastic GCS of 20 to 40 mm Hg inter-
face pressure at the ankle reduce the
severity of PTS after LE DVT.
A separate RCT involving 169 patients
with a first or recurrent proximal LE DVT
after receiving 6 months of standard
treatment to wear GCS or not was con-
ducted.121 The incidence of PTS was 11
patients (13.1%) in the treatment group
compared with 17 individuals (20.0%) in
the control group. No venous ulceration
was observed in either group, with
symptom relief significantly in favor of
compression treatment during the first
year but not thereafter. The conclusion
reached was that prolonged use of GCS
after proximal DVT significantly reduces
symptoms and signs of postthrombotic
skin changes.
In the evidence-based guideline by the
Finnish Medical Society Duodecim,
immediate bandaging for compression
during the acute phase of DVT (up to the
groin, if needed) is recommended in cir-
cular rather than figure-eight turns.31 In
addition, the patient should be mobilized
as soon as clinically possible, and GCS
(class II compression) should be worn
for at least 2 years.
Pooled results from 4 RCTs in another
systematic review122 in patients with
confirmed proximal LE DVT used com-
pression bandaging (inelastic or elastic),
with or without early ambulation, as an
intervention for PTS.122 Results stressed
the importance of activating the calf
muscle pump in addition to compression
bandaging, a message echoed by other
authors more recently.123
The lack of uniformity in reporting stan-
dards, such as the timing, duration, and
degree of compression interface pres-
sure, among other descriptors, makes it
difficult for meaningful comparisons
among studies. This concern has been
raised by more than one investigative
group.98,122–125
In summary, mechanical compression
(eg, with IPC or compression bandaging,
activation of the calf muscle pump), with
or without ambulation, is the corner-
stone in the treatment of PTS. The inter-
vention strategy is primarily focused on
decreasing venous pressure in the
involved lower extremity, enhancement
of the microcirculation, and reduction of
the edema. The efficacy in treating PTS
after confirmed acute LE DVT and its
development during the subacute period
or as a debilitating chronic condition
thereafter do favor the early application
and prolonged use of mechanical com-
pression. The lack in uniformity of the
methods and prescriptive protocols
followed in the use of mechanical com-
pression lends itself to controversy. Nev-
ertheless, the preponderance of quality
evidence does warrant a strong
recommendation.
Action Statement 14: Provide
management strategies to
prevent recurrent VTE and
minimize secondary VTE
complications
Physical therapists should monitor
patients who may develop long-term
consequences of VTE (eg, LE DVT
recurrence, PTS severity) and pro-
vide management strategies in order
to improve quality of life. (Evi-
dence quality: V; Recommendation
strength: P–Best Practice)
Action statement profile
Aggregate evidence quality: Level V
Benefit: Decreasing the incidence of LE
DVT recurrence and minimizing the
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severity of PTS signs and symptoms in
order to enhance functional mobility and
a person’s quality of life experience
Risk, Harm, Cost: Improper fit of
mechanical compression can lead to skin
irritation, ulceration, and interruption of
blood flow.
Benefit-Harm Assessment: Preponder-
ance of benefit over harm
Value Judgments: None
Intentional Vagueness: No specific
types of mechanical compression were
recommended. Physical therapists
should work within their health care sys-
tem to develop institution-specific
protocols.
Role of Patient Preference: Ease of
use, comfort level, and ability to operate
mechanical compression equipment
properly
Exclusions: Patients who have severe
peripheral neuropathy, arterial insuffi-
ciency, decompensated heart failure,
dermatologic diseases, or lesions may
have contraindications to selective
mechanical compression modes.
Summary of evidence
Whether or not a VTE (ie, LE DVT, PE, or
PTS) has a clear cause (eg, surgery,
trauma, forced immobilization) or is
unprovoked (ie, in the absence of a
known risk factor), physical therapists
should remain vigilant in screening
patients for signs and symptoms of recur-
rent VTE.126 It is estimated that the risk
of recurrence can reach 5% to 10% dur-
ing the first 6 to 12 months127 and 10% to
30% within 5 years128 following a docu-
mented first-episode VTE. According to
one recent CPG, the rate of VTE recur-
rence for patients not on long-term anti-
coagulation is 5% per year.36 When phar-
macologic anticoagulation is provided,
the recurrence rate for VTE within the
first 6 months was reported to be less
than 2.5% in one RCT129 and between
1.3% and 7.1% over a period of 18 to 24
months in another RCT.130 Nevertheless,
the incidence of fatal and nonfatal VTE
recurrence in patients who are anticoag-
ulated following confirmed VTE in the
short term of 3 months was reported to
be 0.4% and 3%, respectively, in one
meta-analysis,131 and a fatality incidence
due to PE of 1.68% was found in a large
cohort study.132 These findings serve to
underscore the importance of having
physical therapists monitor patients for
VTE recurrence regardless of whether
over the short term or the long term.
The ability of a clinician to accurately
predict level of risk for recurrent VTE
(eg, low versus high) has been investi-
gated using the Pulmonary Embolism
Severity Index (PESI) clinical prediction
rule and found to be of merit.129,133 Addi-
tionally, the use of global clinical judg-
ment that takes into account all of a
patient’s signs and symptoms (ie,
unstructured clinician gestalt) may be
superior to clinical prediction rule
use.130
The ability to distinguish or recognize
that PTS is present is important for the
clinician to determine. Postthrombotic
syndrome is defined as a combination of
clinical signs and symptoms occurring
after an LE DVT. One study examined 6
different scoring systems that are
intended to document the presence and
severity of PTS based on variable clinical
signs (ie, 11) and symptoms (ie, 12) used
between them.114 Because PTS also
involves a patient’s subjective report of
symptoms, using the objective PTS indi-
cator of skin pigmentation changes that
highly correlate with findings from
duplex sonography for venous reflux
occlusion was advocated.
Thrombosis resolution is often incom-
plete, with as many as 50% of legs
affected by DVT still having residual vein
thrombosis years after the LE DVT is first
diagnosed.98 The negative impact on
generic life-of-quality measures (eg,
36-Item Short-Form Health Survey [SF-
36] sections for physical functioning and
bodily pain) has life-quality consequence
comparable to chronic medical condi-
tions such as diabetes and heart fail-
ure.117 It is prudent, therefore, that phys-
ical therapists recognize signs and
symptoms of PTS and intervene with
education, hydration, early mobilization,
mechanical compression, and referral for
medication when appropriate (refer to
key Action Statement 3). For example,
mechanical compression aims to manage
factors responsible for the pathogenesis
of VTE (ie, Virchow’s triad of hyperco-
agulopathy, venous stasis, and endothe-
lial damage) by reducing swelling, accel-
erating venous return, and improving
muscle pump function.122
In summary, patients who have a prior
history of VTE are at high risk for recur-
rent VTE, especially when they are
immobilized or are of advanced age. It is
judicious to screen for VTE recurrence
using a clinical prediction rule (eg, PESI,
Padua score, Wells criteria for LE DVT;
Geneva Risk Score) for objective docu-
mentation purposes, although global
clinical judgment that would favor inter-
vention for secondary VTE prevention
should not be overlooked. Once VTE is
diagnosed, clinical practice has shifted
away from immobilization with bed rest
and toward early ambulation with or
without adjunctive mechanical compres-
sion. From the literature examined, the
degree to which recurrent VTE is treated
as a secondary prevention should be a
priority. Thus, clinical judgment and
expert opinion remain for deciding the
clinical actions to take.
Conclusion
The major findings of this CPG are the
following:
• Physical therapists should play a
large role in identifying patients
who are at high risk for a VTE.
Once these individuals are identi-
fied, preventive measures such as
referral for medication, initiation of
activity or mobilization, mechanical
compression, and education should
be implemented to decrease the
risk of a first or reoccurring VTE.
• Physical therapists should be aware
of the signs and symptoms of an LE
DVT. When signs and symptoms
are present, the likelihood of an LE
DVT should be determined through
the Wells criteria for LE DVT, and
results should be shared with the
interprofessional team to consider
treatment options.
• In patients with a diagnosed LE
DVT, once a medication’s therapeu-
tic levels or an acceptable time
period has been reached after
administration, mobilization should
begin. Although there are risks
associated with mobilization, the
risk of inactivity is greater.
• Complications following LE DVT
can continue for years or even a
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lifetime. Physical therapists can
help decrease these complications
through education, mechanical
compression, and exercise.
Implementation
In order to implement and disseminate
the recommendations of this CPG, the
GDG has taken or is in the process of
taking the following steps:
• Preliminary sharing of CPG recom-
mendations at APTA’s Combined
Sections Meeting 2015.
• Open access to the CPG and all
reference materials.
• Creation of a pocket guide about
VTE for physical therapists.
• Creation of patient brochures and
information flyers about the role of
physical therapists in preventing
VTE and managing patients with LE
DVT.
• Production of podcasts about the
CPG aimed at physical therapists.
• Presentations on the CPG by the
GDG at local, state, regional, and
national seminars.
• Creation of checklist and sample
evaluation forms incorporating the
recommendations of the CPG.
In order to implement these recommen-
dations, physical therapists and the
entire health care team should take the
following steps:
• Integrate key action statements
within this article into clinical prac-
tice. Making resources easily acces-
sible in the clinic, such as lists of
signs and symptoms of LE DVT,
copies of the Wells criteria for LE
DVT tool, and the algorithms in this
CPG, are some examples.
• Form interprofessional teams that
address VTE and ensure all provid-
ers know about and then imple-
ment the recommendations in this
CPG. This recommendation may be
done through embedding risk
assessment into standardized exam-
ination forms or working with
referral sources to encourage early
mobilization after diagnoses of
VTE. As demonstrated in the areas
of early mobilization in the inten-
sive care unit and diabetes and
chronic pain management, inter-
professional teams are effective
when attempting to change the cul-
ture of an organization to improve
patient outcomes.134–136
• Physical therapists need to seek out
membership in these interprofes-
sional committees and serve as clin-
ical champions in the areas of VTE
prevention and management. As
movement specialists, physical
therapists understand the impor-
tance of mobilization and activity
and have the ability to modify inter-
ventions based on medical history
and patient problems. Physical
therapists can add greatly to the
scope and depth of these teams.
Research Needs
Although researchers have addressed
multiple aspects of VTE management,
there are still many unanswered ques-
tions. A few future research questions
that are specific to the physical therapy
management are listed below:
• Does aggressive screening for LE
DVT lead to a decline in the inci-
dence of PE?
• Does the implementation of guide-
lines for mobilization of patients
with LE DVT lead to earlier mobili-
zation and improved patient
outcomes?
• How should patients with UE DVT
be treated by physical therapists?
• What are guidelines for mobiliza-
tion of individuals with a hemo-
dynamically unstable PE?
• What is the appropriate degree of
graded compression (eg, elastic,
inelastic stockings, IPC) and timing
of treatment intervention for PTS
and LE DVT prevention?
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